{
    "organizations": [],
    "uuid": "f1528d5d70967cf0fa7506190325595c4fb43677",
    "author": "",
    "url": "https://www.reuters.com/article/brief-amicus-announces-additional-data-i/brief-amicus-announces-additional-data-in-pompe-disease-phase-1-2-study-idUSFWN1PX1KF",
    "ord_in_thread": 0,
    "title": "BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 7, 2018 / 9:40 PM / Updated 3 minutes ago BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study Reuters Staff 1 Min Read \nFeb 7 (Reuters) - Amicus Therapeutics Inc: \n* AMICUS THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE DATA IN POMPE DISEASE PHASE 1/2 STUDY AT 14TH ANNUAL WORLDSYMPOSIUMâ„¢ \n* AMICUS THERAPEUTICS INC - CONSISTENT AND DURABLE RESPONSES ACROSS KEY MEASURES OF SAFETY, FUNCTIONAL OUTCOMES AND BIOMARKERS OUT TO MONTH 12 IN TRIAL \n* AMICUS THERAPEUTICS INC - VERY LOW RATE (<1%) OF INFUSION ASSOCIATED REACTIONS MAINTAINED AFTER 550+ INFUSIONS IN TRIAL Source text for Eikon: Further company coverage:",
    "published": "2018-02-07T23:39:00.000+02:00",
    "crawled": "2018-02-07T23:50:24.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "additional",
        "data",
        "pompe",
        "disease",
        "phase",
        "study",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "amicus",
        "therapeutic",
        "inc",
        "amicus",
        "therapeutic",
        "announces",
        "additional",
        "positive",
        "data",
        "pompe",
        "disease",
        "phase",
        "study",
        "14th",
        "annual",
        "amicus",
        "therapeutic",
        "inc",
        "consistent",
        "durable",
        "response",
        "across",
        "key",
        "measure",
        "safety",
        "functional",
        "outcome",
        "biomarkers",
        "month",
        "trial",
        "amicus",
        "therapeutic",
        "inc",
        "low",
        "rate",
        "infusion",
        "associated",
        "reaction",
        "maintained",
        "infusion",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}